ERG and cancer: Interestingly, nuclear FUS granules have already been reported to associate with RNA polymerase II (RNA Pol II), and the N-terminus of FUS, which can phase-separate and is also the transcriptional activator domain of FUS-CHOP and FUS-ERG fusion proteins observed in cancer, is sufficient to target the SWI/SNF chromatin remodelling complex (5,52–56).